TimesSquare Capital Management LLC lessened its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 17.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 97,400 shares of the company’s stock after selling 21,114 shares during the quarter. TimesSquare Capital Management LLC’s holdings in Krystal Biotech were worth $24,013,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of KRYS. Royal Bank of Canada grew its stake in Krystal Biotech by 145.2% during the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock valued at $294,000 after purchasing an additional 964 shares in the last quarter. AQR Capital Management LLC lifted its holdings in Krystal Biotech by 29.9% during the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after buying an additional 2,792 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Krystal Biotech by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock worth $2,870,000 after buying an additional 688 shares during the last quarter. Empowered Funds LLC bought a new position in Krystal Biotech during the 1st quarter worth approximately $218,000. Finally, Cetera Investment Advisers lifted its holdings in Krystal Biotech by 107.9% during the 2nd quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock worth $597,000 after buying an additional 2,255 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.
Krystal Biotech Trading Up 0.5%
Shares of NASDAQ KRYS opened at $293.30 on Wednesday. The company has a market cap of $8.65 billion, a price-to-earnings ratio of 39.21 and a beta of 0.50. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $319.48. The stock’s 50 day simple moving average is $269.52 and its 200 day simple moving average is $255.22.
Wall Street Analyst Weigh In
KRYS has been the topic of a number of research analyst reports. Jefferies Financial Group increased their target price on Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Weiss Ratings raised Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, April 9th. Wolfe Research initiated coverage on Krystal Biotech in a report on Friday, March 27th. They set a “peer perform” rating on the stock. Wall Street Zen raised Krystal Biotech from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Citigroup increased their target price on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $324.11.
Read Our Latest Stock Analysis on KRYS
Insider Buying and Selling
In related news, Director Dino A. Rossi sold 18,950 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $261.41, for a total value of $4,953,719.50. Following the sale, the director owned 78,691 shares of the company’s stock, valued at approximately $20,570,614.31. This trade represents a 19.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $263.21, for a total value of $6,580,250.00. Following the completion of the sale, the insider directly owned 1,403,155 shares in the company, valued at approximately $369,324,427.55. This trade represents a 1.75% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 116,664 shares of company stock worth $31,136,828. Company insiders own 13.10% of the company’s stock.
Krystal Biotech Profile
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Read More
- Five stocks we like better than Krystal Biotech
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report).
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
